Standardizing the Management of Patients With Coronary Microvascular Dysfunction
NCT06025994 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 123
Last updated 2026-02-19
Summary
The SAMCRO is an all comers, prospective, randomized, multicenter, open-label study with blinded adjudicated evaluation of outcomes (PROBE). The diagnosis of angina in non obstructive coronary artery disease (ANOCA) will be confirmed with coronary artery angiography and with the invasive assessment of coronary microvascular dysfunction (CMD) and coronary vasomotion. At least 120 ANOCA patients with invasively confirmed CMD will be randomized to i) multi-domain lifestyle intervention (experimental arm) vs. ii) standard of care (control arm). All patients will undergo follow-up visits at 6, 12, 24, 36, 48 and 60 months. The study endpoints will be the improvement of angina status and quality of life as assessed by validated questionnaires at one year. All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) dietary counselling, ii) strict management of cardiovascular (CV) and metabolic risk factors, iii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iv) exercise training and v) psychological intervention. Patients randomized to the control group will be managed according to current guidelines. The angina status will be assessed by the Seattle Angina Questionnaire (SAQ). Quality of life will be assessed using the EuroQoL (EQ5D-5L). Anxiety and depression will be assessed using the Beck Depression Inventory (BDI).
Conditions
- Coronary Artery Disease
- Microvascular Angina
- Microvascular Ischemia of Myocardium
Interventions
- OTHER
-
MULTI-DOMAIN LIFESTILE INTERVENTION
All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
Sponsors & Collaborators
-
Università degli Studi di Ferrara
collaborator OTHER -
Abbott Medical Devices
collaborator INDUSTRY -
Consorzio Futuro in Ricerca
lead OTHER
Principal Investigators
-
Gianluca Campo · University Hospital of Ferrara
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-10
- Primary Completion
- 2026-02-10
- Completion
- 2029-02-10
Countries
- Italy
Study Locations
More Related Trials
-
Identification of Biomarkers in Subjects With Coronary Syndrome (PLAQUE Study)
NCT06103357 ·Status: RECRUITING
-
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
NCT06600178 ·Status: RECRUITING ·Phase: PHASE1
-
Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients
NCT05392959 ·Status: TERMINATED ·Phase: PHASE4
-
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
NCT04848220 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease
NCT05762952 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease
NCT06717074 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of ONO-1101 in Patients Scheduled for Coronary Angiography
NCT00560209 ·Status: COMPLETED ·Phase: PHASE2
-
Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
NCT01649960 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
NCT03626662 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
NCT02487732 ·Status: COMPLETED ·Phase: PHASE4
-
GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
NCT02377336 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
NCT00269906 ·Status: COMPLETED ·Phase: PHASE3
-
Bacteria in Atherosclerotic Plaques and Adverse Events
NCT06935279 ·Status: COMPLETED
-
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography
NCT04338165 ·Status: UNKNOWN ·Phase: PHASE2
-
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
NCT01327846 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
NCT02284048 ·Status: UNKNOWN ·Phase: PHASE4
-
Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
NCT05083299 ·Status: COMPLETED
-
Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)
NCT06250790 ·Status: RECRUITING
-
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
NCT01663402 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
NCT01226602 ·Status: COMPLETED ·Phase: PHASE1
-
CER-001 Atherosclerosis Regression ACS Trial
NCT02484378 ·Status: COMPLETED ·Phase: PHASE2
-
PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes
NCT03159559 ·Status: UNKNOWN ·Phase: PHASE4
-
Study Effect of VIA-2291 on Vascular Inflammation
NCT00358826 ·Status: COMPLETED ·Phase: PHASE2
-
Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody
NCT04141579 ·Status: COMPLETED ·Phase: NA
-
Study of the Vascular Effects of Serelaxin
NCT01979614 ·Status: COMPLETED ·Phase: PHASE2